Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1997; 77(06): 1179-1181
DOI: 10.1055/s-0038-1656134
DOI: 10.1055/s-0038-1656134
Platelets
The Leu33/Pro Polymorphism (PIA1/PIA2 ) of the Glycoprotein IIIa (GPIIIa) Receptor Is Not Related to Myocardial Infarction in the ECTIM Study
Further Information
Publication History
Received 25 October 1996
Accepted after resubmisssion 12 February 1997
Publication Date:
26 July 2018 (online)
Summary
The GPIIb/IIIa receptor complex may contribute to acute coronary syndromes by mediating platelet aggregation. The Leu33/Pro polymorphism (PlAl/PlA2) of the GPIIIa has recently been shown to be associated with CHD in a small case-control study. We have investigated this polymorphism in a large multicenter study of patients with myocardial infarction and controls and found no difference in the distribution of allele and genotype frequencies between cases and controls.
-
References
- 1 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-250
- 2 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor complex in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
- 3 Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-2380
- 4 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094
- 5 Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy P, Luc G, Richard JL, Ducimetiére P, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease:the ECTIM Study. Arterioscler Thromb 1992; 12: 701-707
- 6 Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644
- 7 WHO MONICA Project principal investigators. The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease):a major international collaboration. J Clin Epidemiol 1988; 41: 105-114
- 8 Jin Y, Dietz HC, Nurden A, Bray PF. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993; 82: 2281-2288
- 9 Saiki RK. Genetic analysis of enzymatically amplified β-globin and HLA-DQA genomic DNA with allele specific oligonucleotide probes. Nature 1987; 324: 163-166
- 10 Marian AJ, Brugada R, Kleinman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1071-1072
- 11 Carter AM, Osseigerning N, Grant PJ. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335: 1072-1073
- 12 Osborn SV, Hampton KK, Smillie D, Channer KS, Daly ME. Platelet glycoprotein IIIa gene polymorphism and myocardial infarction. Lancet 1996; 348: 1309-1310
- 13 Odawara M, Matsunuma A, Yamashita K. Platelet glycoprotein IIIa PlA polymorphism and Japanese diabetic patients with coronary heart disease. Lancet 1996; 348: 1310